Hamilton Lane is an alternative investment firm specializing in private markets for institutional and high-net-worth clients. It offers fund-of-funds, secondaries, co-investments and customized private equity and private credit programs, alongside advisory and reporting services. The firm’s edge is long track record, large proprietary deal and performance databases, and multi-strategy access to illiquid assets without clients having to build a full internal private markets team.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 176 | — | 53.7 | -34.4% |
| Q3 2025 | 190.9 | — | 70.9 | 19.5% |
| Q4 2025 | 198.6 | — | 58.4 | -15.8% |
| Q1 2026 | 193.6 | — | 66.2 | -4.1% |
| Q2 2026 | 275.3 | 56.5% | 80.5 | 49.7% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Mirum Pharmaceuticals, Inc. (MIRM), Hancock Whitney Corporation (HWC), RadNet, Inc. (RDNT), Dianthus Therapeutics, Inc. (DNTH), Casella Waste Systems, Inc. (CWST), VSE Corporation (VSEC)